ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery

Clinical research organization ICON plc (NASDAQ:ICLR) stock is surging on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2025 sales guidance.

To read more about ICLR stock, click here.

The Dublin-based company reported quarterly sales of $2.02 billion on Wednesday after-hours, up 0.8% year over year and beating the consensus of $1.97 billion.

Icon reported adjusted earnings of $3.26 per share, beating the consensus of $3.20.

CEO Dr. Steve Cutler said, “ICON made solid progress in quarter two despite the continuing challenges within the clinical development and macro-economic environments.  ICON’s innovative solutions continue to resonate with customers, leading to strong progression in gross business wins in the quarter, which increased 11% sequentially over quarter one.”

Gross business wins in the quarter were $2.97 billion, representing an increase of 10.6% from quarter one 2025.

Also Read: Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare ...